Kosan BioSciences -- KOSN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: idos	4/16/2007 8:02:45 AM
	of 933

AP Kosan Drug Does Not Affect Heart Monday April 16, 7:58 am ET Kosan Biosciences Cancer Drug Does Not Produce Condition Leading to Irregular Heartbeat HAYWARD, Calif. (AP) -- Biotech drug developer Kosan Biosciences Inc. said Monday that its cancer drug candidate tanespimycin passed a key safety test. Kosan said preclinical and clinical studies showed that tanespimycin did not affect the heart's QTc interval, a measure of the heart's electrical cycle. A prolonging of the QTc interval can lead to an irregular rhythm in the heart's lower chambers. The company said electrocardiogram monitoring and analyses were performed in four early stage clinical trials in more than 85 patients. Kosan is testing tanespimycin to treat multiple myeloma, a cancer of the plasma cells in the blood, and breast cancer that has spread to other parts of the body.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next